Document Detail


Neuroprotection in subarachnoid hemorrhage.
MedLine Citation:
PMID:  20876512     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Despite advances in aneurysm ablation and the initial management of patients presenting with aneurysmal subarachnoid hemorrhage, delayed cerebral ischemia remains a significant source of morbidity. Traditionally, delayed cerebral ischemia was thought to be a result of vasospasm of the proximal intracranial vessels, and clinical trials have relied largely on radiographic evidence of vasospasm as a surrogate for functional outcome. However, a number of trials have demonstrated a dissociation between angiographic vasospasm and outcome, and more recent data suggest that other mechanisms of injury, such as microvascular dysfunction and complex neuronal-glial interactions, may influence the development of delayed ischemic deficit after aneurysmal subarachnoid hemorrhage. Our evolving understanding of the pathophysiology of delayed cerebral ischemia may offer the opportunity to test new therapeutic strategies in this area and improve clinical trial design.
Authors:
Daniel T Laskowitz; Brad J Kolls
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Stroke; a journal of cerebral circulation     Volume:  41     ISSN:  1524-4628     ISO Abbreviation:  Stroke     Publication Date:  2010 Oct 
Date Detail:
Created Date:  2010-09-29     Completed Date:  2010-11-01     Revised Date:  2013-07-03    
Medline Journal Info:
Nlm Unique ID:  0235266     Medline TA:  Stroke     Country:  United States    
Other Details:
Languages:  eng     Pagination:  S79-84     Citation Subset:  IM    
Affiliation:
Departments of Medicine Neurology, Duke University, Durham NC 27710, USA. danl@neuro.duke.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Brain / blood supply
Humans
Neuroprotective Agents / therapeutic use*
Subarachnoid Hemorrhage / drug therapy*
Vasospasm, Intracranial / drug therapy*
Grant Support
ID/Acronym/Agency:
R41 NS056856/NS/NINDS NIH HHS; R41 NS056856-01A2/NS/NINDS NIH HHS
Chemical
Reg. No./Substance:
0/Neuroprotective Agents
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Modulation of the postischemic immune response to improve stroke outcome.
Next Document:  Can molecular and cellular neuroprotection be translated into therapies for patients?: yes, but not ...